Search Cancer Clinical Trials
Recruiting
This research study is studying Chimeric Antigen Receptor (CAR)-37 T Cells (CAR-37 T Cells) for treating people with relapsed or refractory CD37+ hematologic malignancies and to understand the side effects when treated with CAR-37 T Cells. - Chimeric Antigen Receptor (CAR)-37 T Cells (CAR-37 T Cells) is an investigational treatment
- Hematologic Malignancy
- Leukemia
- Lymphoma
- Lymphoma, B-Cell
- Lymphoma, T-Cell
- Lymphoma, Non-Hodgkin
- CAR-37 T cells
Phase 1
Interventional
Primary Outcome:
- Dose Limiting Toxicity
- The occurrence of study related adverse events
Secondary Outcome:
- Disease Specific Response
- Overall Survival
- Progression Free Survival
18
June 19, 2020
- Gender: All
- Minimum age: 18 Years
- Maximum age: N/A
- Healthy volunteers: No
Marcela V. Maus, M.D.,Ph.D.
Massachusetts General Hospital
A Phase I Clinical Trial With CAR-37 T Cells for the Treatment of Patients With Relapsed or Refractory CD37+ Hematologic Malignancies
NCT04136275
Source: Clinicaltrials.gov. Through our founding membership in the Dana-Farber/Harvard Cancer Center, an NCI-designated Comprehensive Cancer Center, these clinical trials are conducted at the Massachusetts General Hospital Cancer Center and may be available at other partner institutions.